Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision…

• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• MG
  Massachusetts General Hospital
• YU
  Yale University
• KP
  Kaiser Permanente
• FH
  F. Hoffmann-La Roche
• CW
  Case Western Reserve University
• SO
  School of Medicine, Case Western Reserve University
• IT
  Intarcia Therapeutics
• NI
  National Institute for Health and Care Research
• UO
  University of Sydney
• UV
  Universiteit van Amsterdam
• UO
  University of Toronto
• NN
  Novo Nordisk
• UŁ
  Uniwersytet Łódzki
• EA
  European Association for the Study of Diabetes
• UD
  Université de Nantes
• S
  Servier
• LD
  Lilly Deutschland
• UO
  University of Ioannina
• SO
  School of Medicine, University of Kansas